<DOC>
	<DOCNO>NCT01130883</DOCNO>
	<brief_summary>This post-marketing observational study ( PMOS ) conduct prospective , single-arm , single-country , multicenter format . The investigational site consult room GPs ( general practitioner ) , pneumologists center experience treatment patient acute infection trachea , bronchus , AECB ( acute exacerbation chronic bronchitis ) CAP ( mild community-acquired pneumonia ) . Since post-marketing observational study , Klacid SR prescribe usual manner accordance term local market authorization regard dose , population indication well local guideline . Objective : describe effectiveness treatment repeat administration Klacid SR patient acute tracheitis , acute tracheobronchitis acute bronchitis ; patient acute exacerbation chronic bronchitis ( AECB ) mild community-acquired pneumonia ( CAP ) receive Klacid SR treatment 6 week 24 month prior Klacid SR dose administer within study .</brief_summary>
	<brief_title>Evaluation Effectiveness Treatment After Repeated Administration Klacid®SR</brief_title>
	<detailed_description>Follow-up participant enable three visit period . At Screening Visit decision Klacid SR therapy dose 500 -1000 mg daily make . The Second Visit occur 8 - 16 day study initiation . The Last Visit phone call participant 30 day initiation treatment . Study visit define `` V1 '' = Screening Visit , `` V2 '' = Visit Klacid SR therapy terminate `` V3 '' = Phone call 30 day initiation Klacid SR therapy .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Tracheitis</mesh_term>
	<criteria>Men , woman least 18 year old . Patients treat Klacid®SR 6 week 24 month prior start PMOS . Patients : acute tracheitis , acute tracheobronchitis , acute bronchitis , mild communityacquired pneumonia acute exacerbation chronic bronchitis Patients without previous administration Klacid®SR patient use Klacid®SR le 6 week ago 24 month ago . The information previous administration Klacid®SR base physician record patient anamnesis . Patients know hypersensitivity macrolide antibiotic Patients document renal impairment ( creatinine clearance 30 ml/min ) . Patients document liver parenchyma impairment ( AST , ALT GMT &gt; 3x high level comparison norm ) Concomitant therapy follow drug : astemizole , cisapride , colchicine , pimozide , terfenadine ergotamine dihydroergotamine Pregnancy Breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>acute tracheitis</keyword>
	<keyword>acute tracheobronchitis acute bronchitis</keyword>
	<keyword>acute exacerbation chronic bronchitis</keyword>
	<keyword>mild community-acquired pneumonia</keyword>
</DOC>